ArcherDX CEO: Scale the deciding factor in choosing $1.4B acquisition over going public
BOULDER — ArcherDX Inc. CEO Jason Myers said his company would have had a “white-hot” initial public offering, but opted to take a $1.4 billion takeover offer from Invitae Corp. (NYSE: NVTA) because of the potential to spread its oncology genomic testing platform to a wider base.
In an interview with BizWest Tuesday morning, Myers confirmed that the San Francisco-based Invitae offered to acquire the company shortly after ArcherDX filed paperwork this month to raise up to $100 million in an…
Related Posts
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
Biopharmaceutical company AmideBio LLC has received a $1.93 million grant from the federal government for…
-
Boulder Community Health this month became the first facility in Colorado to offer patients a…
-
Columbine Health Systems will host Dementia Week, a series of free events devoted to educating…
